Consensus Cytek Biosciences, Inc.

Equities

CTKB

US23285D1090

Real-time Estimate Cboe BZX Other stock markets 02:30:54 2024-06-06 pm EDT			5-day change	1st Jan Change
6 ^USD	+4.71%		+5.63%	-34.21%

02:45pm	Cytek Biosciences Board Approves $50 Million Share Buyback Plan	MT
May. 29	Sector Update: Health Care Stocks Lean Lower Premarket Wednesday	MT

Evolution of the average Target Price on Cytek Biosciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

16b3e8.RZEMVuE6L-2DPmEMblKOeXEQmew2QCbvFZYYh6zDRck.ItNAPoVwfZS1aFB9LwDnDEhX7d1xN0ShdM5Svpi3A74tyToV1X582ddOLA~0a1aa4f42a02324013fd1d1bf88e7f96

Analyst Recommendations on Cytek Biosciences, Inc.

Piper Sandler Adjusts Price Target on Cytek Biosciences to $8.50 From $10, Maintains Overweight Rating	May. 13	MT
Cytek Biosciences Insider Sold Shares Worth $269,600, According to a Recent SEC Filing	Mar. 20	MT
Piper Sandler Trims Price Target on Cytek Biosciences to $10 From $11, Maintains Overweight Rating	Mar. 06	MT
Stephens Initiates Cytek Biosciences With Overweight Rating, Price Target is $9	Dec. 14	MT
Morgan Stanley Trims Price Target on Cytek Biosciences to $7 From $8, Maintains Equalweight Rating	Nov. 09	MT
Morgan Stanley Cuts Cytek Biosciences' Price Target to $8 From $13, Keeps Equalweight Rating	23-10-24	MT
Raymond James Initiates Cytek Biosciences With Market Perform Rating	23-07-19	MT
Morgan Stanley Adjusts Price Target on Cytek Biosciences to $13 From $14, Maintains Equal-Weight Rating	23-05-11	MT
Goldman Sachs Adjusts Cytek Biosciences' Price Target to $12 From $14, Keeps Buy Rating	23-05-10	MT
Piper Sandler Adjusts Price Target on Cytek Biosciences to $15 From $18, Maintains Overweight Rating	23-03-07	MT
Morgan Stanley Trims Cytek Biosciences' Price Target to $14 From $15, Maintains Equalweight Rating	23-03-02	MT
Goldman Sachs Adjusts Cytek Biosciences' Price Target to $14 From $16, Keeps Buy Rating	23-03-02	MT
Piper Sandler Adjusts Cytek Biosciences' Price Target to $16 from $12, Maintains Overweight Rating	22-08-18	MT
Morgan Stanley Adjusts Price Target on Cytek Biosciences to $15 From $11, Maintains Equalweight Rating	22-08-12	MT
Goldman Sachs Adjusts Cytek Biosciences' Price Target to $17 From $15, Keeps Buy Rating	22-08-11	MT
Goldman Sachs Raises Cytek Biosciences' Price Target to $15 From $12, Buy Rating Maintained	22-07-14	MT
Piper Sandler Adjusts Price Target on Cytek Biosciences to $12 From $17, Reiterates Overweight Rating	22-05-16	MT
Morgan Stanley Lowers Price Target for Cytek Biosciences to $11 From $18, Maintains Equalweight Rating	22-05-12	MT
Goldman Sachs Lowers Cytek Biosciences Price Target to $12 From $14, Buy Rating Maintained	22-05-12	MT
Goldman Sachs Adjusts Cytek Biosciences' Price Target to $14 from $28, Keeps Buy Rating	22-04-13	MT
Piper Sandler Adjusts Cytek Biosciences' Price Target to $17 From $20, Reiterates Overweight Rating	22-03-01	MT
Morgan Stanley Adjusts Cytek Biosciences Price Target to $18 From $27, Maintains Equalweight Rating	22-02-15	MT
CYTEK BIOSCIENCES : Cowen & Co Initiates Coverage on Cytek Biosciences With Outperform Rating	21-08-17	MT
CYTEK BIOSCIENCES : Morgan Stanley Starts Cytek Biosciences at Equal-Weight With $26 Price Target	21-08-17	MT
CYTEK BIOSCIENCES : Goldman Sachs Starts Cytek Biosciences at Buy With $28 Price Target	21-08-17	MT